Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now shows revision v3.5.4, replacing the previous v3.5.3, indicating a frontend update.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page’s displayed ClinicalTrials.gov revision/version updates from **v3.5.2** to **v3.5.3** without changing study details.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision metadata updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check105 days agoChange DetectedThe page now includes an additional condition keyword 'Fallopian tube cancer' and a new resource link to the Genetic and Rare Diseases Information Center. The page revision is updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.